Radiation Therapy for Mesothelioma: 3 Primary Uses and What to Expect

Radiation therapy plays a fundamentally different role in mesothelioma treatment compared to most other cancers. Approximately 3,000 Americans are diagnosed with mesothelioma each year, and radiation is incorporated into 30 to 40% of their treatment plans — almost always in combination with surgery or chemotherapy rather than as a standalone approach. Rather than serving as a primary curative treatment, radiation addresses mesothelioma through three specific applications: reducing local recurrence risk after surgery, controlling symptoms in advanced disease, and in specialized protocols, preceding surgery as a preparatory step.

What Are the Key Facts About Radiation Therapy and Mesothelioma?

• Radiation therapy alone rarely cures mesothelioma due to the disease's diffuse spread along pleural surfaces, making complete irradiation at curative doses impractical
• IMRT (intensity-modulated radiation therapy) is the recommended modern technique because it shapes radiation beams precisely to pleural mesothelioma's irregular three-dimensional geometry
• Adjuvant hemithoracic radiation following EPP surgery typically delivers 45–60 Gy to the entire affected pleural space over 4–6 weeks
• Palliative radiation uses lower doses of 20–30 Gy delivered over a shorter course to relieve symptoms including pain, breathlessness, and superior vena cava obstruction
• Prophylactic irradiation of port sites (biopsy tracts, drain insertion points, chest tube sites) is practiced at some centers to prevent tumor seeding along procedure tracks, though its benefit remains debated based on conflicting clinical trial data
• The SMART (Surgery for Mesothelioma After Radiation Therapy) protocol uses 25 Gy in 5 fractions before EPP surgery and is offered at select specialized mesothelioma centers including Princess Margaret Cancer Centre in Toronto
• Proton beam therapy is an emerging option at highly specialized centers that further reduces radiation dose to adjacent critical structures compared to conventional photon-based X-ray radiation
• Most radiation treatment sessions last 15–30 minutes per visit, with adjuvant courses typically running 4–6 weeks of daily weekday treatment
• Common side effects of thoracic radiation include radiation pneumonitis, esophagitis, fatigue, and skin changes — the severity depending on dose and treatment technique
• Peritoneal mesothelioma is treated with radiation far less frequently than pleural mesothelioma because the close proximity of radiosensitive bowel and abdominal organs limits safe dose delivery

What Is the Role of Radiation Therapy in Mesothelioma Treatment?

Unlike lung cancer or prostate cancer — where radiation can serve as a definitive primary treatment — mesothelioma presents unique anatomical challenges that prevent radiation alone from controlling the disease. Pleural mesothelioma spreads as a diffuse coating across the entire lining of the chest cavity, encasing the lung, diaphragm, and mediastinum. Irradiating this entire surface at doses sufficient to kill cancer cells would simultaneously deliver lethal doses to the underlying lung tissue and adjacent heart.

This is why radiation for mesothelioma almost always works in combination — either as part of a trimodality regimen (chemotherapy plus surgery plus radiation), as palliative relief in patients who are not surgical candidates, or as a targeted prophylactic measure at specific sites.

> "Radiation is one of the most misunderstood tools in mesothelioma treatment — and one of the most underutilized when it's appropriate. The question isn't whether to use radiation, it's about sequence and intent. Palliative radiation can give a patient months of meaningful pain relief. Adjuvant radiation after EPP can extend local control significantly. Knowing which scenario you're in changes everything." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

The National Cancer Institute's treatment guidelines for mesothelioma note that radiation therapy may be offered as part of combined-modality treatment and is most effective when used in a carefully sequenced, multidisciplinary treatment plan. According to SEER data, approximately 3,000 Americans are diagnosed with mesothelioma annually — and radiation is a component of care for a meaningful subset of that population, particularly those who undergo surgical resection. A comprehensive overview of all mesothelioma treatment options, including surgery, chemotherapy, and immunotherapy, is available from WikiMesothelioma.

What Are the 3 Primary Types of Radiation Therapy Used for Mesothelioma?

1. Adjuvant Hemithoracic Radiation

Adjuvant radiation is delivered after extrapleural pneumonectomy (EPP) surgery, which removes the affected lung, pleura, diaphragm, and pericardium. With the lung no longer present, radiation oncologists can safely deliver higher doses to the now-empty pleural space — typically 45–60 Gy using IMRT — targeting the entire hemithorax where cancer cells may remain after surgery.

The goal of adjuvant radiation is to reduce local recurrence. Even after technically complete EPP surgery, microscopic disease frequently remains along the pleural margins, in lymph nodes, or along surgical tracks. Adjuvant radiation targets these residual cells before they can develop into clinical recurrences.

IMRT is the standard technique for adjuvant hemithoracic radiation because it allows radiation oncologists to deliver dose to the entire former pleural space while significantly reducing exposure to the contralateral lung, heart, liver, and esophagus. Without IMRT, the risk of life-threatening radiation pneumonitis in the remaining lung would make this dose range unsafe.

2. Palliative Radiation

Palliative radiation is used in patients with advanced mesothelioma who are not candidates for surgery. The goal is not to eliminate the cancer but to control its most debilitating effects — particularly chest wall pain from tumor invasion, breathlessness from tumor pressure, or symptoms from metastatic deposits in bone or soft tissue.

Palliative radiation typically uses lower doses (20–30 Gy) delivered over shorter courses (1–2 weeks) to minimize treatment burden and side effects. Response rates for pain control are significant — published series report 50–80% of patients experience meaningful symptom relief after palliative thoracic radiation, with many experiencing improvement within days to weeks of completing treatment.

3. Prophylactic Port-Site Irradiation

Mesothelioma cells can seed along the tracks left by thoracentesis needles, chest tubes, VATS ports, or biopsy instruments — a phenomenon called procedure-track metastasis. Prophylactic radiation delivers 21 Gy in 3 fractions to these specific sites to sterilize any seeded tumor cells before they can establish visible lesions.

The clinical evidence here is mixed. Some European trials have shown a meaningful reduction in procedure-track recurrences with prophylactic irradiation; other randomized trials have found no statistically significant benefit over observation. Current practice varies by center, and NCCN guidelines note the controversial nature of this indication.

When Is Adjuvant Radiation Therapy Recommended After Mesothelioma Surgery?

Adjuvant radiation is most commonly recommended after extrapleural pneumonectomy (EPP) rather than after pleurectomy/decortication (P/D). The distinction is important: EPP removes the entire lung, creating space for hemithoracic radiation at doses high enough to be therapeutically meaningful. After P/D — which preserves the lung — delivering a full hemithoracic dose would inevitably irradiate the remaining lung tissue to doses that cause unacceptable pulmonary toxicity in most patients.

Patients who are most likely to receive adjuvant radiation after EPP include those with epithelioid histology (the most common and most treatment-responsive cell type), limited nodal involvement, absence of distant metastases, and adequate performance status to tolerate a 4–6 week course of radiation following major thoracic surgery.

> "I always tell patients preparing for EPP: surgery is the first act, but radiation is the insurance policy for what the surgeon couldn't see. The microscopic residual disease that sits along a margin or a lymph node station is exactly what radiation is designed to address." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

The timing between EPP surgery and adjuvant radiation varies, but most protocols begin radiation 4–8 weeks after surgery to allow adequate wound healing. Chemotherapy may be administered before surgery (neoadjuvant), after surgery but before radiation, or concurrently with radiation depending on the treatment protocol used at the treating center.

For patients considering surgery, understanding the full sequence of a trimodality regimen — including the radiation component — is essential. The differences between EPP and pleurectomy/decortication significantly affect whether adjuvant radiation is technically feasible and whether it fits within the recommended treatment plan.

How Does Palliative Radiation Help Mesothelioma Patients Manage Symptoms?

Palliative radiation for mesothelioma addresses some of the disease's most debilitating symptoms with precision that systemic medications alone often cannot match. When tumor growth causes direct invasion of chest wall structures — particularly ribs, intercostal nerves, and brachial plexus — the resulting pain can be severe and refractory to standard analgesics.

Targeted radiation to these tumor deposits reduces their size and activity, decreasing pressure on pain-sensitive structures. Published response rates are consistently in the 50–80% range for pain relief, with many patients experiencing improvement within days to 2 weeks of starting treatment. Duration of response varies, but symptom control often lasts several months.

Beyond pain, palliative radiation addresses:

• Superior vena cava (SVC) obstruction: Mediastinal tumor progression can compress the SVC, causing facial swelling, arm edema, and breathing difficulty. Emergency palliative radiation can rapidly decompress the SVC and restore venous drainage.
• Spinal cord compression: Rare in mesothelioma but urgent when it occurs — radiation is the primary treatment to prevent or limit neurological deficits.
• Chest wall mass reduction: Large visible chest wall nodules from procedure-track metastases can be effectively debulked with local radiation.
• Symptom control at distant sites: When mesothelioma spreads to bone or soft tissue, site-directed palliative radiation can control localized pain.

Palliative radiation is generally well-tolerated compared to curative or adjuvant regimens because lower total doses are used and the treatment course is shorter. Patients typically experience mild fatigue and localized skin changes during treatment, with symptoms resolving within weeks of completing the course.

What Is the SMART Protocol and Who Is an Appropriate Candidate?

SMART — Surgery for Mesothelioma After Radiation Therapy — inverts the conventional trimodality sequence. Instead of surgery first followed by radiation, patients receive high-dose short-course hemithoracic radiation (25 Gy in 5 fractions, 5 Gy per day for 5 consecutive days), then undergo EPP surgery within approximately one week of completing radiation.

The radiobiological rationale for this reversal is substantial. Delivering radiation while the lung remains in place allows the treating radiation team to use the lung itself as a partial shield for surrounding structures. High doses can be delivered to the pleural surfaces while the lung absorbs a substantial portion of the dose in the target region — and because the lung will be surgically removed within days, its radiation exposure is clinically inconsequential.

Additionally, delivering radiation before surgical manipulation may reduce the risk of tumor seeding that can occur when cancer cells are disturbed by surgical instruments.

> "The SMART protocol represents a genuine paradigm shift in how we think about radiation timing. By delivering radiation before surgery — and accepting that we're deliberately irradiating tissue we'll remove — we can potentially sterilize the entire operative field before the first incision. For the right patient at the right center, the survival data is genuinely promising." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

Published results from Princess Margaret Cancer Centre have reported median overall survival exceeding 24 months in selected epithelioid patients treated with SMART, with some patients achieving long-term disease control. These are better outcomes than historical series reported for conventional trimodality treatment. However, SMART requires a specialized multidisciplinary team with experience in both high-dose preoperative radiation and major thoracic surgery, and is not available at all centers. Patients can review current open mesothelioma clinical trials including SMART-related protocols at WikiMesothelioma.

Ideal SMART candidates typically have epithelioid cell type (better prognosis and response), clinical stage T1–3 disease, no nodal involvement, adequate pulmonary reserve, and excellent performance status. Patients should seek evaluation at centers that specifically perform SMART to determine eligibility.

Patients considering clinical trial options should explore the available mesothelioma clinical trials in 2026, as several trials are evaluating radiation combined with novel systemic agents.

What Side Effects Should Mesothelioma Patients Expect From Radiation Therapy?

Radiation side effects depend on the area treated, the total dose delivered, and the technique used. For thoracic mesothelioma radiation, the major categories of concern are:

Radiation Pneumonitis

Inflammation of lung tissue is the most significant concern for pleural mesothelioma radiation, particularly when hemithoracic radiation is used after P/D (lung-sparing surgery) or when the contralateral lung receives scatter dose after EPP. Symptoms include cough, shortness of breath, low-grade fever, and, in severe cases, respiratory failure. With modern IMRT planning that carefully constrains dose to remaining lung tissue, rates of severe (Grade 3+) pneumonitis have been substantially reduced compared to earlier radiation techniques. Most cases of mild-to-moderate pneumonitis resolve with corticosteroid treatment.

Esophagitis

When radiation fields include the mediastinum, the esophagus receives dose that can cause inflammation (esophagitis) — leading to painful swallowing, difficulty eating, and occasional esophageal stricture. Patients are typically advised to eat soft foods during and immediately after thoracic radiation, and severe esophagitis may require temporary tube feeding. Symptoms typically resolve within 2–4 weeks of completing treatment.

Cardiac Effects

The heart is adjacent to the left pleura and receives dose during left-sided mesothelioma radiation. Acute pericarditis (inflammation of the heart lining) can occur, causing chest pain and arrhythmias. Longer-term effects include constrictive pericarditis, which can develop months to years after treatment. Careful IMRT planning includes dose constraints for the entire cardiac volume and specific heart substructures.

Fatigue and Skin Changes

Fatigue is nearly universal during radiation therapy and typically peaks toward the end of treatment and in the 2–3 weeks following. It usually improves substantially within 4–6 weeks post-treatment. Skin in the radiation field may become red, dry, or mildly blistered — reactions generally manageable with topical preparations and resolve after treatment ends.

Late Effects

Long-term effects of thoracic radiation can include pulmonary fibrosis (permanent scarring of lung tissue), lymphedema if lymph node stations are heavily irradiated, constrictive pericarditis, radiation-induced rib fractures (rare), and, with very long latency, secondary malignancy. Modern treatment planning significantly reduces — but does not eliminate — the risk of these late effects.

How Do You Find a Radiation Oncologist With Mesothelioma Experience?

Mesothelioma is uncommon enough that most radiation oncologists encounter only a handful of cases in their careers. Patients receive substantially better outcomes when they are treated at centers where radiation oncologists have specific experience planning and delivering radiation for this disease.

The top mesothelioma treatment centers — including Memorial Sloan Kettering, MD Anderson, Brigham and Women's/Dana-Farber, Penn Medicine, and University of Chicago — have dedicated pleural disease programs with radiation oncologists who specialize in IMRT planning for thoracic malignancies. An overview of top mesothelioma treatment centers can help patients identify where specialized radiation expertise is available.

When seeking a radiation oncology consultation for mesothelioma, key questions to ask include:

• How many mesothelioma patients do you treat with radiation per year?
• Do you use IMRT for pleural mesothelioma? Do you offer proton therapy?
• Do you offer the SMART protocol, and am I a candidate?
• What dose and fractionation do you recommend for my situation?
• What constraints do you use to protect my heart, remaining lung, esophagus, and liver?
• What clinical trials involving radiation are currently enrolling at your center?

Understanding the full spectrum of treatment options — surgery, chemotherapy, immunotherapy, and radiation — is essential before committing to any treatment plan. The mesothelioma surgery options guide provides important context for understanding how radiation integrates with the surgical decision. Patients navigating these complex decisions may also benefit from a free case assessment to connect with resources specific to their situation.

Radiation therapy may also be relevant to compensation planning. Patients who underwent asbestos exposure at their workplace — including industrial plants, shipyards, and construction sites — may be entitled to asbestos trust fund compensation or legal claims regardless of their current treatment status. The asbestos trust fund guide explains the options available.

Frequently Asked Questions About Radiation Therapy for Mesothelioma

When is radiation therapy recommended for mesothelioma?

Radiation therapy for mesothelioma is recommended in three primary situations: as adjuvant treatment following extrapleural pneumonectomy (EPP) surgery to reduce the risk of local recurrence along the pleural space; as palliative treatment to control pain, relieve breathlessness, or reduce nerve compression in patients with advanced disease who are not surgical candidates; and prophylactically to prevent tumor seeding along biopsy tracts or drain insertion sites. Radiation is rarely used as a standalone curative treatment because mesothelioma spreads diffusely along pleural surfaces in a pattern that makes complete surgical clearance and full-dose irradiation difficult. The NCCN designates IMRT-based radiation as the preferred technique when radiation is used.

What is the SMART protocol for mesothelioma radiation therapy?

SMART stands for Surgery for Mesothelioma After Radiation Therapy. Unlike the conventional sequence of surgery followed by radiation, the SMART protocol delivers short-course, high-dose hemithoracic radiation therapy — typically 25 Gy in 5 fractions — before extrapleural pneumonectomy (EPP) surgery, with surgery performed within 1 week of completing radiation. The protocol was developed at Princess Margaret Cancer Centre in Toronto and has shown promising survival outcomes in selected patients with epithelioid pleural mesothelioma, with some series reporting median overall survival exceeding 24 months. SMART is not widely available and requires a specialized multidisciplinary center.

What is IMRT and why is it used for mesothelioma radiation treatment?

Intensity-modulated radiation therapy (IMRT) is a sophisticated radiation delivery technique that uses computer-controlled linear accelerators to modulate the intensity of the radiation beam from multiple angles simultaneously. This allows radiation oncologists to sculpt the radiation dose to conform tightly to the irregular three-dimensional shape of pleural mesothelioma while simultaneously reducing the dose to adjacent critical structures — including the remaining or contralateral lung, heart, liver, esophagus, and spinal cord. NCCN guidelines specifically recommend IMRT when radiation is incorporated into mesothelioma treatment plans.

What side effects does radiation therapy cause for mesothelioma patients?

Radiation therapy for mesothelioma causes side effects that depend on which area of the chest is treated, the total dose, and how the radiation is delivered. The most common side effects of thoracic radiation include radiation pneumonitis (inflammation of the lung tissue), esophagitis causing difficulty swallowing, fatigue, skin redness or irritation in the treated area, and potential cardiac effects such as pericarditis. With IMRT and modern treatment planning, the rates of severe radiation pneumonitis have been substantially reduced compared to older techniques. Late effects can include pulmonary fibrosis and constrictive pericarditis.

Can radiation therapy cure mesothelioma?

Radiation therapy alone does not cure mesothelioma in the vast majority of cases and is not used as a standalone curative treatment. The diffuse, sheet-like growth pattern of pleural mesothelioma across large pleural surfaces makes it technically impossible to irradiate the entire disease burden at tumoricidal doses without causing fatal toxicity to surrounding structures, particularly the underlying lung. Radiation is most effective as part of a multimodal treatment approach — most commonly after EPP surgery, which removes the involved lung and pleura, creating a geometry in which higher radiation doses can be safely delivered to the empty pleural space.

Is radiation therapy used for peritoneal mesothelioma?

Radiation therapy is rarely used for peritoneal mesothelioma compared to pleural mesothelioma. The peritoneal cavity presents different anatomical challenges — close proximity of radiosensitive bowel, kidneys, and liver makes full-dose radiation impractical. Peritoneal mesothelioma is primarily treated with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC), which has demonstrated 5-year survival rates exceeding 50% in select patients at specialized centers. Radiation may occasionally be used palliatively in peritoneal mesothelioma to control localized pain or tumor growth.